BRIEF published on 02/12/2026 at 07:35, 1 month 14 days ago Nicox maintains its PEA-PME status for 2026 PEA-PME Euronext Growth Paris Investment Ophthalmology Nicox
BRIEF published on 02/12/2026 at 07:35, 1 month 14 days ago Nicox maintient son statut PEA-PME pour 2026 PEA-PME Euronext Growth Paris Investissement Ophtalmologie Nicox
PRESS RELEASE published on 02/12/2026 at 07:30, 1 month 14 days ago Nicox confirme son éligibilité au PEA-PME Nicox confirme son éligibilité au PEA-PME pour l'année à venir, permettant aux investisseurs de continuer à intégrer ses actions dans les comptes PEA PME PEA-PME Investissement Fiscalité Ophtalmologie Nicox
BRIEF published on 02/10/2026 at 07:35, 1 month 16 days ago Nicox présentera des données clés lors de la réunion annuelle de l'AGS en 2026. Essais Cliniques Nicox NCX 470 Glaucome AGS 2026
BRIEF published on 02/10/2026 at 07:35, 1 month 16 days ago Nicox to Present Key Data at AGS Annual Meeting 2026 Clinical Trials Glaucoma Nicox NCX 470 AGS 2026
PRESS RELEASE published on 02/10/2026 at 07:30, 1 month 16 days ago Nicox to Present Data from NCX 470 Phase 3 Studies at American Glaucoma Society (AGS) Annual Meeting 2026 Nicox to present NCX 470 Phase 3 data at AGS Annual Meeting 2026 with podium presentations showcasing clinical study results and efficacy of the ophthalmic solution Clinical Study Ophthalmology Nicox NCX 470 AGS Annual Meeting 2026
PRESS RELEASE published on 02/10/2026 at 07:30, 1 month 16 days ago Nicox : Présentation des données des études de Phase 3 de NCX 470 au congrès annuel 2026 de l’American Glaucoma Society (AGS) Nicox présente les données des études de Phase 3 de NCX 470 au congrès annuel 2026 de l'AGS, démontrant l'efficacité de leur nouveau produit pour le glaucome Ophtalmologie Nicox NCX 470 Études De Phase 3 Congrès AGS
BRIEF published on 01/20/2026 at 07:35, 2 months 6 days ago Nicox Announces 2026 Conference Participation and Data Presentations Scientific Data Ophthalmology NCX 470 Conference Participation 2026 Events
BRIEF published on 01/20/2026 at 07:35, 2 months 6 days ago Nicox annonce sa participation à la conférence de 2026 et la présentation de ses données. Ophtalmologie NCX 470 Participation À La Conférence Événements De 2026 Données Scientifiques
BRIEF published on 01/20/2026 at 07:35, 2 months 6 days ago Nicox annonce ses participations à plusieurs congrès en 2026 Ophtalmologie Nicox NCX 470 Glaucome Congrès 2026
Published on 03/26/2026 at 23:00, 1 hour 12 minutes ago FutureGen Industries Announces Closing of Debt Settlement
Published on 03/26/2026 at 22:05, 2 hours 7 minutes ago BlackBerry to Announce Fourth Quarter and Fiscal Year 2026 Results on April 9, 2026
Published on 03/26/2026 at 22:00, 2 hours 12 minutes ago Clean Air Metals Receives Provincial Funding and Provides Update on the Thunder Bay North Project
Published on 03/26/2026 at 22:00, 2 hours 12 minutes ago Green Bridge Metals Reports Visible Copper Sulfide Mineralization in Initial 2026 Titac Drilling, Duluth Complex Minnesota
Published on 03/26/2026 at 21:00, 3 hours 12 minutes ago Worksport Reports Record FY 2025 Results, Issues $35M–$42M 2026 Revenue Guidance; Targets Initial Cash Flow Positivity
Published on 03/26/2026 at 20:48, 3 hours 24 minutes ago Dermapharm Holding SE repurchases 4,299,190 shares under its public share buyback offer
Published on 03/26/2026 at 19:20, 4 hours 52 minutes ago Critical Path Institute Launches 'One to Millions' to Reshape the Future of Individualized Medicine at Global Scale
Published on 03/26/2026 at 19:09, 5 hours 3 minutes ago 2CRSi SA: Résultats 1er Semestre 2025/26 : Chiffre d'Affaires 204,7 M€ (x9,8) EBITDA de 9,6 M€ (x4,6)
Published on 03/26/2026 at 19:09, 5 hours 3 minutes ago 2CRSi SA: First Half 2025/26 Results: Revenue of €204.7 million (x9.8) EBITDA of €9.6 million (x4.6)
Published on 03/26/2026 at 18:17, 5 hours 55 minutes ago Eiffage se renforce au capital de Getlink et porte sa participation à 29,40 % du capital
Published on 03/26/2026 at 18:17, 5 hours 55 minutes ago Eiffage strengthens its position in Getlink capital
Published on 03/26/2026 at 18:00, 6 hours 12 minutes ago Arrêté des comptes au 31 décembre 2025 et perspectives 2026
Published on 03/26/2026 at 18:00, 6 hours 12 minutes ago LABORATOIRES EUROMEDIS - Fin du contrat de liquidité
